Trajenta Duo contains linagliptin that belongs to a class of drugs called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). It is prescribed in the treatment of Type 2 Diabetes mellitus. Metformin is an agent belonging to the biguanide class of antidiabetics. It is used in the treatment of non-insulin-dependent diabetes mellitus
Linaglitin has a unique way of controlling blood glucose. GLP-1 and GIP are two most important hormones in body that stimulate insulin secretion in response to food intake. DPP-4 destroys GLP-1 and GIP. This leads to an increase in blood glucose levels as insulin is not secreted as required. Linagliptin inhibits DPP-4 and hence prevents inactivation of GLP-1 and GIP by DPP-4. This allows GLP-1 and GIP to potentiate the secretion of insulin in beta cells of pancreas. It also suppresses glucagon release by the alpha cells in the pancreas that is responsible to increase the glucose content of blood.
Linagliptin has a better safety profile as compared to other drugs in its class and hence can be prescribed in patients with poor kidney function.
Trajenta Duo is a brand from Boehringer Ingelheim pharmaceutical company. Established in 1885, Boehringer Ingelheim is one of the leading companies in India.
Their vision is to develop innovative therapies that can extend patients’ lives. “Making more health” is a company’s initiative with the goal to improve health in communities around the world.